ArticleFrontiers in oncology2021

Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients.

Gedmante Radziuviene et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.